These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8374534)

  • 1. Cyclosporine metabolite pattern in blood from patients with acute GVHD after BMT.
    Christians U; Spiekermann K; Bader A; Schottmann R; Linck A; Wonigeit K; Sewing KF; Link H
    Bone Marrow Transplant; 1993 Jul; 12(1):27-33. PubMed ID: 8374534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The measurement of whole blood pre-treatment cyclosporine A: metabolite ratios predicts the onset of renal dysfunction in recipients of allogeneic stem cell transplantation.
    Stephens E; Bolderson I; Clark B; Kinsey S; Gooi HC; Cook G
    Ann Clin Biochem; 2006 Sep; 43(Pt 5):382-8. PubMed ID: 17022881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors.
    Martin P; Bleyzac N; Souillet G; Galambrun C; Bertrand Y; Maire PH; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2003 Nov; 32(9):881-7. PubMed ID: 14561988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
    Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum HLA class I levels coincide with acute and chronic graft-versus-host disease.
    Liem LM; Koelman CA; Doxiadis II; van Houwelingen JC; Goulmy E; Claas FH
    Bone Marrow Transplant; 1997 Aug; 20(3):227-34. PubMed ID: 9257891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomagnetic CD4+ and CD8+ cell depletion for patients at high risk for severe acute GVHD.
    Jansen J; Hanks S; Akard LP; Thompson JM; Burns S; Chang Q; English D; Garrett P
    Bone Marrow Transplant; 1996 Mar; 17(3):377-82. PubMed ID: 8704690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD.
    Puppo F; Brenci S; Ghio M; Bignardi D; Contini P; Bacigalupo A; Van Lint MT; Scudeletti M; Ferrone S; Indiveri F
    Bone Marrow Transplant; 1996 May; 17(5):753-8. PubMed ID: 8733693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between lymphocyte subsets, after allogeneic bone marrow transplantation, in patients who received tacrolimus and patients who received cyclosporin A.
    Fukuda H; Teshima H; Karasuno T; Hiraoka A; Nakamura H; Masaoka T
    Int J Hematol; 2000 Jan; 71(1):70-4. PubMed ID: 10729997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
    Kumar S; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Harmsen WS; Litzow MR
    Bone Marrow Transplant; 2001 Jun; 27(11):1133-40. PubMed ID: 11551023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
    Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A
    Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matched-pair analysis comparing allogeneic PBPCT and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia.
    Vicent MG; Madero L; Ortega JJ; Martinez A; Gomez P; Verdeguer A; Badell I; Muñoz A; Olive T; Maldonado MS; Bureo E; Cubells J; Diaz MA;
    Bone Marrow Transplant; 2002 Jul; 30(1):9-13. PubMed ID: 12105771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.
    Tanimoto TE; Yamaguchi T; Tanaka Y; Saito A; Tajima K; Karasuno T; Kasai M; Kishi K; Mori T; Maseki N; Morishima S; Miyakoshi S; Kasai M; Ohno Y; Kim SW; Numata A; Kami M; Takaue Y; Mori S; Harada M
    Br J Haematol; 2004 May; 125(4):480-93. PubMed ID: 15142119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
    Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
    Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.